Vaxcyte reports positive Phase 3 trial results for VAX-31 vaccine and raises $1.1B to fund development and launch.

Vaxcyte announced positive topline results from its OPUS-1 Phase 3 trial of the VAX-31 vaccine for adults, meeting all primary endpoints and showing a safety profile comparable to existing vaccines. The company plans to report further Phase 3 trial results in early 2027 and aims to submit a Biologics License Application in the first half of 2028. Vaxcyte also raised approximately $1.1 billion through equity and convertible notes offerings to support its pipeline and potential commercial launch. The company is advancing other vaccine candidates, including VAX-A1 for Group A Streptococcus, with key data expected in 2027.

As of Nov 05, 2026 04:23 WIB, Vaxcyte Inc. common stock (PCVX) is trading at USD 65.44 on Pluang, showing a strong 1-day gain of 7.61%. The stock's market capitalization stands at $9.58 billion with a trading volume of 2,159,747 shares. Pluang investors currently show full buying interest with 100% buy orders and no sell orders.